In response to the MHRA and NICE decisions on lecanemab, Professor Sir Stephen Powis, NHS National Medical Director, said: “The NHS now awaits a final decision from the National Institute for Health and Care Excellence that will look at the clinical benefits and cost-effectiveness of lecanemab and determine if it should be routinely offered by the […]
Read More on the NHS website.